ARSTAT Pharmaceuticals Inc.

Arstat Pharmaceuticals is advancing transformational products that focus on significant unmet needs in women's health. Protected by 12 granted U.S. patents and a European (EPO) patent, the pipeline includes four drug candidates with proven efficacy and safety. Two products are Phase III-ready (confirmed by the FDA), and two other products are ready for Phase IIb. An addressable U.S. market is approximately 50 million women, with projected peak U.S. gross sales exceeding $3.4 billion. This is arguably one of the very best pharmaceutical portfolios in women's health. Arstat's most valuable asset is Nuvocept – the first and only oral contraceptive designed explicitly for women with overweight and obesity The FDA has already endorsed an unprecedented clinical program and a potentially unique label. Nuvocept is expected to dominate a multi-billion-dollar segment of the US contraceptive market and address a high public health priority in the post-Roe world. The Company's Founder, President, and Chief Scientific Officer, Arkady Rubin, Ph.D., with 30+ years of industry experience (J&J, Pfizer). Dr. Rubin is a co-inventor of Ortho Tri-Cyclen Lo, the top-selling oral contraceptive in the U.S. ($1.8B/year in current market conditions.) In addition, we are engaged in proprietary R&D activities. We developed and patented two transformational women's health products: NUVOCEPT - the first and only oral contraceptive designed for women with overweight and obesity (20 million US contraceptive users). Protected by 7 US patents and a European (EPO) patent. PREMRING - first-in-class vaginal ring for uterine fibroids and endometriosis (a much-needed solution for >15 million US women). Protected by 2 US Protected by 2 US patents. ENHANTA - first-in-class single non-hormonal therapy for painful and heavy menstrual periods (25 million US women). Protected by 3 US patents. Please visit the company's website (www.arstatinfo.com) for further details.